Vidac Pharma celebrated a significant milestone on September 19: The US Patent and Trademark Office (USPTO) has granted the biopharmaceutical company a broad patent that protects the unique mechanisms of its cancer therapies. This protection includes, in particular, the active ingredients VDA-1102 and VDA-1275, which specifically reverse the metabolic mechanism of cancer cells – known as the Warburg effect. Vidac Pharma is the only company in the world pursuing this approach. The goal is to normalize cell functionality, stop tumor growth and reactivate the immune system. With this exclusive position in the US market, the patent success paves the way for the further expansion of the product pipeline and strengthens the market position of the innovative company.
News & Events